{"id":688089,"date":"2026-07-12T19:22:11","date_gmt":"2026-07-12T19:22:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/uk\/688089\/"},"modified":"2026-07-12T19:22:11","modified_gmt":"2026-07-12T19:22:11","slug":"single-dose-psilocybin-led-to-robust-antidepressant-response","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/uk\/688089\/","title":{"rendered":"Single Dose Psilocybin Led to Robust Antidepressant Response"},"content":{"rendered":"

The excitement around psilocybin research for the treatment of depressive disorders has spurred momentum worldwide. Psilocybin, a naturally occurring hallucinogen found in over 200 species of mushrooms, has long been recognized as having profound psychoactive effects (Smausz et al, 2022). However, the Controlled Substances Act of 1970 severely restricted research on hallucinogenic and psychedelic substances. It was not until 1992 that the National Institute on Drug Abuse<\/a> and the FDA, recognizing the potential benefits of psychedelic drugs, removed restrictions and permitted psychedelic research to include human subjects (Doblin, 1992). <\/p>\n

Since then, studies evaluating psilocybin as a potential option for the treatment of depressive disorders have surged (Nichols, 2000; Smausz, 2022 ). On April 18, 2026, President Trump<\/a> signed an executive order further accelerating research and expanding access to psychedelic drugs for serious mental illnesses. <\/p>\n

Properties of psilocybin <\/p>\n

Psilocybin itself does not exhibit much effect until it undergoes a metabolic conversion in the body to psilocin, the pharmacologically active compound. Psilocin, a 5-HT serotonin receptor agonist, binds strongly to 5-HT2A receptors and, to a lesser extent, 5-HT1A and 5-HT2C receptors (Adeyinks et al, 2025). Psilocybin has consistently been shown to have low addictive potential and is considered to have the safest profile among psychedelic drugs (Metaxa et al, 2024; Adeyinks, 2025).<\/p>\n

New treatments urgently needed for depression<\/p>\n

Depression<\/a> affects an estimated 300 million people around the world and is a leading cause of disability (Metaxa, 2024). While antidepressant<\/a> medications have led to tremendous strides in treating depression, some patients have inadequate responses or intolerable side effects. It can take several weeks to notice benefits, and full remission of symptoms can take months (Metaxa, 2024). Depression often behaves as a chronic illness<\/a>, with a high likelihood of relapse<\/a> without treatment, especially in those who have experienced multiple episodes.<\/p>\n

New study shows benefits of single dose psilocybin for depressive disorder<\/p>\n

A study from Sweden published in May 2026 in the Journal of the American Medical Association (JAMA) highlighted results showing that just a single dose of psilocybin had both short-term and long-term antidepressant benefits for patients with depressive disorders (Yngwe et al, 2026). <\/p>\n

The study was unique in being a double-blind, placebo<\/a>-controlled randomized clinical trial (RCT) of patients with a diagnosis of moderate to severe recurrent major depressive disorder (MDD). According to the authors, this design has not previously been used in studies of psilocybin for MDD. Prior research has focused on psilocybin for patients with treatment-resistant depression (TRD) and cancer-related depression. However, patients with MDD comprise a substantial cohort that can benefit immensely from the rapid mood boost (Yngwe, 2026). The study design minimizes bias<\/a> as participants are randomly assigned to either the treatment group (those receiving psilocybin) or a control group (those receiving placebo), and neither the patients nor the researchers know which group they are in. <\/p>\n

Double-blind RCTs typically have high internal validity for assessing treatment effects. Concerns with prior studies relate to the inclusion of past psychedelic users as well as the use of crossover designs in which both groups sequentially received the same treatments. This study excluded participants with a history of psychedelic use.<\/p>\n

The study methods and results<\/p>\n

The primary objective was to assess the antidepressant effects of a single, 25 mg oral dose of psilocybin in patients with MDD by day 8. Thirty-five participants who were diagnosed with moderate to severe MDD were included, with 17 patients randomized to the psilocybin group and 18 to the placebo group (the placebo used in the study was a vitamin called niacin). Participants received a single dose of either psilocybin 25 mg or placebo (niacin 100 mg) in identical-appearing capsules. Over the course of 17 days, they also received 5 psychotherapeutic support sessions.<\/p>\n

Response to treatment was measured by the Montgomery-\u00c5sberg Depression Rating Scale (MADRS). This clinician-administered scale measures 10 areas affected by depression, including mood, sleep, appetite<\/a>, pessimism<\/a>, and suicidal<\/a> thoughts. Each section is scored on a scale of 0-6, with higher total scores indicating more severe depressive symptoms. <\/p>\n

Depression Essential Reads<\/p>\n

The study successfully met its endpoint, showing a significant improvement in depressive symptoms, with a mean reduction of 7.27 points on the MADRS (95% CI, P=0.01) in patients who received psilocybin compared to placebo at day 8 of treatment. In addition, significant improvement in the psilocybin group versus the placebo group was present on days 15 and 42. At 6 weeks, the psilocybin group had a remission rate of 52.9% compared to 5.9% for the placebo group. The beneficial effects noted in the psilocybin group versus placebo were no longer noted at 12 months.<\/p>\n

Separately, the patient self-rated version of the scale, known as MADRS-S, revealed a significant reduction in depressive symptoms in the psilocybin group over the placebo group already at day 2. This improvement persisted for more than 3 months (through day 102), as did other secondary outcomes that were measured, such as quality of life and functional disability. <\/p>\n

Psilocybin was generally well tolerated, with some reports of transient, mild to moderate side effects. Two participants in the psilocybin group reported persistent, severe anxiety<\/a> and required additional medical support. Limitations of the study include the modest sample size of 35 patients, possible expectation bias related to the self-selection of patients, and the use of physicians who were involved in the study as raters, which may have decreased blinding accuracy.<\/p>\n

Future direction<\/p>\n

Given that depressive disorders affect hundreds of millions of individuals, the urgency to find new treatments that will improve clinical outcomes, shorten response times, and decrease side effects is clear. Maintenance of rigorous standards for research methodology is imperative in this process of new drug development. Psilocybin remains a promising additional treatment for recurrent depressive disorders due to its rapid onset of action and potential benefits for relapse prevention.<\/p>\n","protected":false},"excerpt":{"rendered":"The excitement around psilocybin research for the treatment of depressive disorders has spurred momentum worldwide. Psilocybin, a naturally…\n","protected":false},"author":2,"featured_media":688090,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[59,57,58,50,56,54,55],"class_list":["post-688089","post","type-post","status-publish","format-standard","has-post-thumbnail","category-united-kingdom","tag-gb","tag-great-britain","tag-greatbritain","tag-news","tag-uk","tag-united-kingdom","tag-unitedkingdom"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/688089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=688089"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/688089\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/688090"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=688089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=688089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=688089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}